Atopic Disorders Carry a Measurable Mental Health Burden in UK Primary Care

A large UK primary care cohort has linked atopic disorders with a higher subsequent burden of mental ill health. In a retrospective open cohort drawn from records spanning 1995 to early 2022, people with food allergy, drug allergy, anaphylaxis, urticaria, or allergic rhino-conjunctivitis were compared with matched unexposed individuals. The size of the dataset gives the findings unusual clinical weight: 2,491,086 exposed patients were matched to 3,120,719 unexposed patients on sex, age, and deprivation quintile at baseline.

The composite mental health outcome included severe mental illness, anxiety, depression, eating disorders, obsessive-compulsive disorder, and self-harm. During follow-up, 229,124 exposed individuals developed a mental ill health outcome versus 203,450 in the comparison group. Incidence was higher in the atopic cohort at 144.13 per 10,000 person-years, compared with 117.82 per 10,000 person-years in unexposed patients. After adjustment, the overall association remained modest but persistent, with an adjusted hazard ratio of 1.16 (95% CI 1.15 to 1.17).

One result stood out immediately: anxiety was the strongest individual signal.

Anxiety Drove the Strongest Signal Across Individual Outcomes

Among the prespecified psychiatric outcomes, anxiety showed the greatest relative excess. The adjusted hazard ratio for anxiety reached 1.22, with a remarkably tight 95% confidence interval of 1.21 to 1.23. For clinicians, that pattern is not trivial. Anxiety is often the mental health disorder most directly entangled with chronic allergic symptoms, unpredictable flares, dietary vigilance, fear of anaphylaxis, sleep disruption, and the social burden of visible or relapsing skin and mucosal disease.

The composite endpoint also matters because it captures a broad spectrum of psychological morbidity rather than a single diagnosis. In real-world primary care, patients rarely present with neatly separated syndromes. A person with recurrent urticaria may also develop anticipatory anxiety around eating, sleep loss from itching, or depressive symptoms after repeated symptom recurrence. A patient with food allergy may become hypervigilant in restaurants, schools, or workplaces, and that constant threat perception can reinforce both anxiety and avoidance behaviors. The association observed here is therefore biologically and behaviorally plausible even though the study design does not prove causation.

Baseline Matching Strengthened the Cohort Comparison

The cohort was assembled with careful matching on sex, age within two years, and socioeconomic deprivation using Townsend quintile score. Mean age at cohort entry was 39.42 years in the exposed group and 35.81 years in the unexposed group, with similar broad adult and pediatric representation reflected by the large standard deviations in both groups. Those baseline similarities reduce one major source of bias in observational work, especially when mental health outcomes can be influenced by age structure and social deprivation.

Covariate adjustment extended beyond the matching variables. The regression models also accounted for alcohol use, smoking status, body mass index, asthma exposure, and eczema exposure at baseline. That matters because atopic disease rarely occurs in isolation. Asthma and eczema can independently shape sleep, school attendance, physical discomfort, and psychological strain. By adjusting for these coexisting conditions, the analysis tried to isolate the contribution of the recorded allergic and atopic disorders under study rather than simply capturing a general atopic phenotype.

A sensitivity analysis that also matched participants for asthma and eczema did not erase the signal. The association remained robust, which makes the excess mental ill health harder to dismiss as a byproduct of two common comorbid atopic diseases.

Clinical Interpretation at the Bedside

The practical reading of these data is straightforward: patients with recorded allergic and atopic disorders in primary care deserve attention to mental health, not just symptom control. Recurrent allergic disease can create a feedback loop in which fear of symptoms intensifies monitoring, avoidance, and sleep disruption, all of which can worsen anxiety and depressive symptoms. Severe allergy also introduces a distinct psychological burden because the consequences of an exposure can feel immediate and potentially catastrophic. Even milder disorders such as urticaria or allergic rhino-conjunctivitis can erode quality of life when symptoms are chronic, unpredictable, or poorly controlled.

The study also carries implications for service design. The conclusion points toward dual delivery of allergy and psychology services. In primary care, that could mean earlier screening for anxiety and depression in people with frequent allergy consultations, more deliberate assessment of self-harm risk when distress is high, and closer coordination between allergy clinicians, general practitioners, and mental health services. Such integration is especially relevant because the study used routine records, the same setting where subtle psychological distress can otherwise remain undocumented until it becomes severe.

What the Cohort Can and Cannot Prove

Observational data of this scale can identify risk patterns, not mechanism. The study did not measure symptom severity, allergen burden, treatment intensity, or patient-level experiences such as fear of exposure, school avoidance, or quality-of-life impairment. It also relied on Read code identification within primary care records, so the results reflect diagnosed and recorded disease rather than the full spectrum of allergic symptoms in the community. Residual confounding remains possible in any retrospective design, even one with extensive covariate adjustment.

Still, the direction of effect is consistent across the composite endpoint and the anxiety signal, and the absolute event counts are large enough to matter in day-to-day practice. Even a modest relative increase becomes clinically important when it is spread across millions of patients and unfolds over decades of follow-up. The main message is not that every patient with an allergy diagnosis will experience psychiatric illness. It is that allergic and atopic disease should now be viewed as a marker for elevated mental health vulnerability in routine care, especially when anxiety symptoms begin to shape behavior, sleep, and adherence.

The study leaves one direct challenge for services: allergy care is already multidisciplinary in many settings, but psychological assessment is rarely built into the pathway with the same consistency. Without that integration, the burden captured in this cohort will continue to surface late, after symptoms have already accumulated.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.